Safety, Tolerability & Pharmacokinetics Study of CNTX-6016 in Healthy Subjects and Subjects With PDN

• Status: Recruiting
• Trial end date: 2022-03-01
• Target enrollment: 0
• Participant gender: All

Summary

A Phase 1b/2a study to evaluate the safety, tolerability and pharmacokinetics of multiple ascending doses of CNTX-6016 in healthy subjects and a single cohort to evaluate painful diabetic neuropathy.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Centrexion Therapeutics

Criteria

Key Inclusion Criteria:

• Is in good general health as determined by Investigator's review.

• Has a body mass index (BMI) between 18 and 35 kg/m2.

• Non- or ex-smoker (> 1 year) and has not used any nicotine containing products within 12 months prior to screening.

• For females, is not currently pregnant and is either of non-childbearing potential or willing to use an adequate method of birth control.

• For males, must agree to use barrier contraception and not to donate sperm

Key Exclusion Criteria:

• Is pregnant, lactating, or planning a pregnancy during the study.

• Tests positive for COVID-19 after screening is complete and subject is confirmed to enroll

• History of or active cardiac disease, including congestive heart failure, angina, or any arrhythmia.

• Has any history or currently active type of cancer except excised or cured basal cell carcinoma.

• Has an immunological disorder such as, but not limited to, human immunodeficiency virus (HIV), acquired, or congenital immune deficiency syndrome; autoimmune diseases, such as, but not limited to, rheumatoid arthritis, systemic lupus erythematosus, seronegative spondyloarthropathies or vasculitis, or any infection.

• Positive urine screen for alcohol, cotinine, THC and/or drugs of abuse

• Has positive screening test for hepatitis B virus (HBV) or hepatitis C virus (HCV).

Key Inclusion Criteria- PDN Cohort

• A diagnosis/history of Type 2 diabetes mellitus

• The pain is present in both feet/legs with symmetrical onset

• The pain is characterized as burning, painful, cold or electrical shocks in nature

• The pain is associated with tingling, numbness, itching or pins and needles type sensations

• The pain has been present and consistent for ≥ 6 months

Key Exclusion Criteria- PDN Cohort

• Diagnosis of Type 1 diabetes

• Has serious or unstable cardiovascular, hepatic, renal, respiratory or hematological illness

• Has a history or currently active type of cancer except excised or cured basal cell carcinoma.

• Has a History of psychological conditions or neurological disorders

• Has a History of lower back pain with radiculopathy

• Has received non-pharmacological treatment for pain within 14 days

• Has a history of frequent and/or severe allergic reactions with multiple medications